Neuromod Devices Ltd., founded in 2010 and headquartered in Dublin, Ireland, develops and commercialises Lenire, a non‑invasive bimodal neuromodulation device for tinnitus. Lenire delivers mild electrical pulses to the tongue via a Tonguetip® combined with auditory stimulation to drive changes in the brain and relieve tinnitus symptoms. The device achieved FDA De Novo approval in March 2023 and holds CE marking in Europe, and its pivotal controlled trial was published in Nature Communications. Neuromod has commercial traction with Lenire available in more than 100 clinics across the USA and in clinics in 14 European countries; 35 USVA facilities have been trained to provide the treatment. Real‑world evidence includes a base of over 1,500 patients and clinic-level results showing high rates of clinically significant improvement. The company plans to use new funding to accelerate sustainable commercial expansion in the USA and Europe and to grow opportunities within the US Department of Veteran Affairs. Neuromod Devices, founded in 2010 by Dr. Ross O’Neill, is a Dublin, Ireland–based medical technology company that designs neuromodulation technologies for underserved chronic conditions. Its lead product, Lenire, is a bimodal neuromodulation device that delivers mild electrical pulses to the tongue via the Tonguetip® combined with auditory stimulation through headphones to treat tinnitus. Lenire has been used in large-scale clinical trials with over 700 patients, is available throughout Europe, and recently received FDA De Novo approval. Since its prior funding round in October 2020 the company has commercialised Lenire across Europe and established a wholly owned US subsidiary, Neuromod USA Inc. The company intends to use the new funding to launch Lenire in the US, pursue opportunities with the US Departments of Defense and Veteran Affairs, expand availability in additional European countries, and advance next-generation product development. The financing structure (equity plus venture debt) supports its planned US market entry and continued commercial expansion. Neuromod is an Irish medical technology company that designs and develops neuromodulation technologies to address tinnitus. Its core product, Lenire®, is a CE-marked, non-invasive bimodal neuromodulation device commercially available in Ireland, Belgium and Germany. The company published results from a 12-week, 326-patient clinical trial in Science Translational Medicine showing that more than 80% of compliant participants saw sustained improvements at 12 months. Proceeds from the €10.5 million Series B will be used to expand European commercialisation, scale up manufacturing, progress a U.S. FDA strategy, and pursue opportunities with the U.S. Department of Veteran Affairs. Neuromod plans to recruit roughly 40 employees over the next 12 months with roles based in Ireland and Germany. The company was founded in 2010 and is headquartered in the Digital Hub, Dublin. Neuromod Devices develops non-invasive neuromodulation technologies and markets Lenire®, a CE‑marked bimodal neuromodulation tinnitus treatment for use under healthcare supervision in Europe. The company opened a Centre of Excellence in tinnitus care in Dublin and plans additional European treatment centres, including one in Hannover by end of 2019 and more during 2020. Neuromod says it has conducted the largest and longest follow-up clinical trials for tinnitus to confirm Lenire®’s efficacy. Proceeds from the recent financing will be used to accelerate European commercialisation and scale manufacturing to meet anticipated demand. The company is also progressing a U.S. regulatory strategy aimed at an FDA submission to enable U.S. market entry. Neuromod is headquartered in the Digital Hub, Dublin, and was founded in 2010 as a spin‑out from Maynooth University. Neuromod Devices develops mutebutton®, a non-invasive bi-modal neuromodulation device that delivers simultaneous auditory stimulation in the ear and sensory stimulation on the tongue to promote beneficial neuroplasticity for chronic tinnitus. The company holds a CE mark for the mutebutton® (awarded October 2014) and a US patent for its technology (awarded September 2015). Neuromod plans to use recent financing to advance dose optimisation and patient sub-typing research and to commence US clinical trials. The company targets an international launch of mutebutton® in 2018. Manufacturing partners M&M Qualtech and Molex and support from Enterprise Ireland are cited as contributors to the company’s growth. To date Neuromod has raised over €8 million ($9 million).

Total raised

$72M

Funding rounds

8

Latest round

Series B

Latest activity

Mar 2025